Renin-angiotensin-aldosterone system blockade in diabetic nephropathy. Present evidences

Journal of Clinical Medicine

Volumn 4, Issue 11, 2015, Pages 1908-1937

  Lozano Maneiro, Luz ^a   Puente García, Adriana ^a  

^a HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

Author keywords

ACE inhibitors; Aldosterone antagonist; Angiotensin receptor blockers; Combined RAAS blockade; Diabetic kidney disease; Diabetic nephropathy; Direct renin inhibitors; Dual RAAS blockade; Mineralocorticoid receptor antagonists; Renin angiotensin aldosterone system blockade

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDOSTERONE; ALISKIREN; ANGIOTENSIN II; CANDESARTAN; CAPTOPRIL; CREATININE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; EPLERENONE; IRBESARTAN; LISINOPRIL; LOSARTAN; MINERALOCORTICOID RECEPTOR; OLMESARTAN; RAMIPRIL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPIRONOLACTONE; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA; VERAPAMIL;

CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; END STAGE RENAL DISEASE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; KIDNEY INJURY; MACROALBUMINURIA; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREMATURE MORTALITY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RESTRICTION;

EID: 85067220145     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4111908     Document Type: Review

References (114)

1. Williams, J.S.; Williams, G.H. 50th anniversary of aldosterone. J. Clin. Endocrinol. Metab. 2003, 88, 2364-2372, doi:10.1210/jc.2003-030490.
2. Ferreira, S.H. A bradykinin-potentiating factor (BPF) present in the venom of bothrops jararaca. Br. J. Pharmacol. Chemother. 1965, 24, 163-169, doi:10.1111/j.1476-5381.1965.tb02091.x.
3. Ng, K.K.; Vane, J.R. Some Properties of Angiotensin Converting Enzyme in the Lung in vivo. Nature 1970, 225, 1142-1144, doi:10.1038/2251142b0.
4. Gradman, A.; Schmieder, R.; Lins, R.; Nussberger, J.; Chiang, Y.; Bedigian, M. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005, 111, 1012-1018, doi:10.1161/01.CIR.0000156466.02908.ED.
5. Roscioni, S.S.; Heerspink, H.J.; Zeeuw, D. The effect of RAAS blockade on the progression of diabetic nephropathy. Nat. Rev. Nephrol. 2014, 10, 77-87, doi:10.1038/nrneph.2013.251.
6. Anderson, S.; Rennke, H.G.; Garcia, D.L.; Brenner, B.M. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int. 1989, 36, 526-536.
7. Fliser, D.; Wagner, K.K.; Loos, A.; Tsikas, D.; Haller, H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J. Am. Soc. Nephrol. 2005, 16, 1135-1140.
8. Lewis, E.J.; Hunsicker, L.G.; Bain, R.P.; Rohde, R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 1993, 329, 1456-1462.
9. Furukawa, M.; Gohda, T.; Tanimoto, M.; Tomino, Y. Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy. Sci. World J. 2013, 2013, doi:10.1155/2013/928197.
10. Andersen, S.; Tarnow, L.; Rossing, P.; Hansen, B.V.; Parving, H.H. Renoprotective effects of angiotensin II receptor blockadein type 1 diabetic patients with diabetic nephropathy. Kidney Int. 2000, 57, 601-606, doi:10.1046/j.1523-1755.2000.00880.x.
11. Lewis, E.J.; Hunsicker, L.G.; Clarke, W.R.; Berl, T.; Pohl, M.A.; Lewis, J.B.; Ritz, E.; Atkins, R.C.; Rohde, R.; Raz, I.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001, 345, 851-860.
12. Brenner, B.M.; Cooper, M.E.; de Zeeuw, D.; Keane, W.F.; Mitch, W.E.; Parving, H.H.; Remuzzi, G.; Snapinn, S.M.; Zhang, Z.; Shahinfar, S.; et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001, 345, 861-869.
13. B.A.; Ficociello, L.H.; Roshan, B.; Warram, J.H.; Krolewski, A.S. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int. 2010, 77, 57-64, doi:10.1038/ki.2009.399.
14. Kasiske, B.L.; Kalil, R.S.; Ma, J.Z.; Liao, M.; Keane, W.F. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann. Intern. Med. 1993, 118, 129-138.
15. Parving, H.H.; Hommel, E.; Jensen, B.R.; Hansen, H.P. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int. 2001, 60, 228-234.
16. Hoogwerf, B.J.; Young, J.B. The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not. Clevel. Clin. J. Med. 2000, 67, 287-293, doi:10.3949/ccjm.67.4.287.
17. Wilmer, W.A.; Hebert, L.A.; Lewis, E.J.; Rohde, R.D.; Whittier, F.; Cattran, C.; Levey, A.S.; Lewis, J.B. Remission of nephrotic syndrome in type 1 diabetes: Long-term follow-up of patients in the Captopril Study. Am. J. Kidney Dis. 1999, 34, 308-314.
18. Hovind, P.; Rossing, P.; Tarnow, L.; Smidt, U.M.; Parving, H.H. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int. 2001, 60, 277-283.
19. Hovind, P.; Rossing, P.; Tarnow, L.; Smidt, U.M.; Parving, H. Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care 2001, 24, 1972-1977.
20. Hovind, P.; Tarnow, L.; Rossing, P.; Carstensen, B.; Parving, H.H. Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2004, 66, 1180-1186.
21. Viberti, G.; Mogensen, C.E.; Groop, L.C.; Pauls, J.F. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994, 271, 275-279.
22. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia 1996, 39, 587-593.
23. Hebert, L.A.; Bain, R.P.; Verme, D.; Cattran, D.; Whittier, F.C.; Tolchin, N.; Rohde, R.D.; Lewis, E.J.; the Collaborative Study Group. Remission of nephrotic range proteinuria in type I diabetes. Kidney Int. 1994, 46, 1688-1693.
24. Steffes, M.W. Affecting the decline of renal function in diabetes mellitus. Kidney Int. 2001, 60, 378-379.
25. Chaturvedi, N.; the EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997, 349, 1787-1792.
26. Newman, D.J.; Mattock, M.B.; Dawnay, A.B.; Kerry, S.; McGuire, A.; Yaqoob, M.; Hitman, G.A.; Hawke, C. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol. Assess. 2005, 9, doi:10.3310/hta9300.
27. Mauer, M.; Zinman, B.; Gardiner, R.; Suissa, S.; Sinaiko, A.; Strand, T.; Drummond, K.; Donnelly, S.; Goodyer, P.; Gubler, M.C.; et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 2009, 361, 40-51, doi:10.1056/NEJMoa0808400.
28. Bilous, R.; Chaturvedi, N.; Sjølie, A.K.; Fuller, J.; Klein, R.; Orchard, T.; Porta, M.; Parving, H.H. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: Three randomized trials. Ann. Intern. Med. 2009, 151, 11-20.
29. Ruggenenti, P.; Fassi, A.; Ilieva, A.P.; Bruno, S.; Iliev, I.P.; Brusegan, V.; Rubis, N.; Gherardi, G.; Arnoldi, F.; Ganeva, M.; et al. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 2004, 351, 1941-1951.
30. Kramer, H.J.; Nguyen, Q.D.; Curhan, G.; Hsu, C.Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003, 289, 3273-3277.
31. Ravid, M.; Brosh, D.; Levi, Z.; Bar-Dayan, Y.; Ravid, D.; Rachmani, R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. 1998, 128, 982-988.
32. Patel, A.; ADVANCE Collaborative Group; MacMahon, S.; Chalmers, J.; Neal, B.; Woodward, M.; Billot, L.; Harrap, S.; Poulter, N.; Marre, M.; et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007, 370, 829-840.
33. De Galan, B.E.; Perkovic, V.; Ninomiya, T.; Pillai, A.; Patel, A.; Cass, A.; Neal, B.; Poulter, N.; Harrap, S.; Mogensen, C.E.; et al. Lowering blood pressure reduces renal events in type 2 diabetes. J. Am. Soc. Nephrol. 2009, 20, 883-892, doi:10.1681/ASN.2008070667.
34. Haller, H.; Ito, S.; Izzo, J.L., Jr.; Januszewicz, A.; Katayama, S.; Menne, J.; Mimran, A.; Rabelink, T.J.; Ritz, E.; Ruilope, L.M.; et al. ROADMAP Trial Investigators Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N. Engl. J. Med. 2011, 364, 907-917, doi:10.1056/NEJMoa1007994.
35. Parving, H.H.; Lehnert, H.; Bröchner-Mortensen, J.; Gomis, R.; Andersen, S.; Arner, P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001, 345, 870-878.
36. Makino, H.; Haneda, M.; Babazono, T.; Moriya, T.; Ito, S.; Iwamoto, Y.; Kawamori, R.; Takeuchi, M.; Katayama, S.; INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007, 30, 1577-1578.
37. De Zeeuw, D.; Remuzzi, G.; Parving, H.H.; Keane, W.F.; Zhang, Z.; Shahinfar, S.; Snapinn, S.; Cooper, M.E.; Mitch, W.E.; Brenner, B.M. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int. 2004, 65, 2309-2320.
38. Remuzzi, G.; Ruggenenti, P.; Perna, A.; Dimitrov, B.D.; de Zeeuw, D.; Hille, D.A.; Shahinfar, S.; Carides, G.W.; Brenner, B.M.; RENAAL Study Group. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results. J. Am. Soc. Nephrol. 2004, 15, 3117-3125.
39. Atkins, R.C.; Briganti, E.M.; Lewis, J.B.; Hunsicker, L.G.; Braden, G.; Champion de Crespigny, P.J.; DeFerrari, G.; Drury, P.; Locatelli, F.; Wiegmann, T.B.; et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am. J. Kidney Dis. 2005, 45, 281-287.
40. Berl, T.; Hunsicker, L.G.; Lewis, J.B.; Pfeffer, M.A.; Porush, J.G.; Rouleau, J.L.; Drury, P.L.; Esmatjes, E.; Hricik, D.; Pohl, M.; et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J. Am. Soc. Nephrol. 2005, 16, 2170-2179.
41. Pohl, M.A.; Blumenthal, S.; Cordonnier, D.J.; De Alvaro, F.; Deferrari, G.; Eisner, G.; Esmatjes, E.; Gilbert, R.E.; Hunsicker, L.G.; de Faria, J.B.; et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations. J. Am. Soc. Nephrol. 2005, 16, 3027-3037.
42. Berl, T.; Hunsicker, L.G.; Berl, T.; Hunsicker, L.G.; Lewis, J.B.; Pfeffer, M.A.; Porush, J.G.; Rouleau, J.L.; Drury, P.L.; Esmatjes, E.; Hricik, D.; Parikh, C.R.; et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann. Intern. Med. 2003, 138, 542-549.
43. Imai, E.; Chan, J.C.; Ito, S.; Yamasaki, T.; Kobayashi, F.; Haneda, M.; Makino, H. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: A multicentre, randomised, placebo-controlled study. Diabetologia 2011, 54, 2978-2986, doi:10.1007/s00125-011-2325-z.
44. Barnett, A.H.; Bain, S.C.; Bouter, P.; Karlberg, B.; Madsbad, S.; Jervell, J.; Mustonen, J.; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N. Engl. J. Med. 2004, 351, 1952-1961.
45. Hirst, J.A.; Taylor, K.S.; Stevens, R.J.; Blacklock, C.L.; Roberts, N.W.; Pugh, C.W.; Farmer, A.J. The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy. Kidney Int. 2012, 81, 674-683, doi:10.1038/ki.2011.413.
46. Nakao, Y.M.; Teramukai, S.; Tanaka, S.; Yasuno, S.; Fujimoto, A.; Kasahara, M.; Ueshima, K.; Nakao, K.; Hinotsu, S.; Nakao, K.; et al. Effects of renin-angiotensin system blockades on cardiovascular outcomes in patients with diabetes mellitus: A systematic review and meta-analysis. Diabetes Res. Clin. Pract. 2012, 96, 68-75, doi:10.1016/j.diabres.2011.11.025.
47. Lacourciere, Y.; Bélanger, A.; Godin, C.; Hallé, J.P.; Ross, S.; Wright, N.; Jean, M.J. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. 2000, 58, 762-769.
48. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl. 2013, 3, 1-150, doi:10.1038/kisup.2012.74
49. Wong, J. Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: A guide for the perplexed. Diabates Vasc. Dis. Res. 2013, 10, 193-201, doi:10.1177/1479164112463710.
50. Pichler, R.H.; de Boer, I.H. Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease. Curr. Diabetes Rep. 2010, 10, 297-305, doi:10.1007/s11892-010-0126-2.
51. Bomback, A.S.; Klemmer, P.J. The incidence and implications of aldosterone breakthrough. Nat. Clin. Pract. Nephrol. 2007, 3, 486-492.
52. Forclaz, A.; Maillard, M.; Nussberger, J.; Brunner, H.R.; Burnier, M. Angiotensin II receptor blockade: Is there truly a benefit of adding an ACE inhibitor? Hypertension 2003, 41, 31-36.
53. De Boer, I.H.; Katz, R.; Cao, J.J.; Fried, L.F.; Kestenbaum, B.; Mukamal, K.; Rifkin, D.E.; Sarnak, M.J.; Shlipak, M.G.; Siscovick, D.S. Cystatin C, albuminuria, and mortality among older adults with diabetes. Diabetes Care 2009, 32, 1833-1838.
54. Menard, J.; Campbell, D.J.; Azizi, M.; Gonzales, M.F. Synergistic effects of ACE inhibition and Ang II antagonism on blood presure, cardiac weigt and renin in spontaneously hypertensive rats. Circulation 1997, 96, 3072-3078.
55. Jacobsen, P.; Andersen, S.; Rossing, K.; Jensen, B.R.; Parving, H.H. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 2003, 63, 1874-1880.
56. Jacobsen, P.; Andersen, S.; Jensen, B.R.; Parking, H.H. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14, 992-999.
57. Mogensen, C.E.; Neldam, S.; Tikkanen, I.; Oren, S.; Viskoper, R.; Watts, R.W.; Cooper, M.E. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan and Lisinopril Microalbuminuria (CALM) study. Br. Med. J. 2000, 321, 1440-1444.
58. Bakris, G.L.; Ruilope, L.; Locatelli, F.; Ptaszynska, A.; Pieske, B.; de Champlain, J.; Weber, M.A.; Raz, I. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial. Kidney Int. 2007, 72, 879-885.
59. Kunz, R.; Friedrich, C.; Wolbers, M.; Mann, J.F. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann. Intern. Med. 2008, 148, 30-48.
60. Mancia, G.; de Backer, G.; Dominiczak, A.; Cifkova, R.; Fagard, R.; Germano, G.; Grassi, G.; Heagerty, A.M.; Kjeldsen, S.E.; Laurent, S.; et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension. J. Hypertens. 2007, 25, 1751-1762.
61. ONTARGET Investigators; Yusuf, S.; Teo, K.K.; Pogue, J.; Dyal, L.; Copland, I.; Schumacher, H.; Dagenais, G.; Sleight, P.; Anderson, C.; et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008, 358, 1547-1559, doi:10.1056/NEJMoa0801317.
62. Mann, J.F.; Schmieder, R.E.; McQueen, M.; Dyal, L.; Schumacher, H.; Pogue, J.; Wang, X.; Maggioni, A.; Budaj, A.; Chaithiraphan, S.; Dickstein, K.; et al. ONTARGET investigators Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372, 547-553, doi:10.1016/S0140-6736(08)61236-2.
63. Fried, L.F.; Duckworth, W.; Zhang, J.H.; O'Connor, T.; Brophy, M.; Emanuele, N.; Huang, G.D.; McCullough, P.A.; Palesvky, P.M.; Seliger, S.; et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin. J. Am. Soc. Nephrol. 2009, 4, 361-368, doi:10.2215/CJN.03350708.
64. Imai, E.; Haneda, M.; Yamasaki, T.; Kobayashi, F.; Harada, A.; Ito, S.; Chan, J.C.; Makino, H. Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: A post-hoc analysis (ORIENT-Hypertension). Hypertens. Res. 2013, 36, 1051-1059, doi:10.1038/hr.2013.86.
65. Persson, F.; Rossing, P.; Schjoedt, K.J.; Juhl, T.; Tarnow, L.; Stehouwer, C.D.A.; Schalkwijk, C.; Boomsma, F.; Frandsen, E.; Parving, H.H. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 2008, 73, 1419-1425, doi:10.1038/ki.2008.68.
66. Parving, H.H.; Persson, F.; Lewis, J.B.; Lewis, E.J.; Hollenberg, N.K.; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 2008, 358, 2433-2446, doi:10.1056/NEJMoa0708379.
67. Parving, H.H.; Brenner, B.M.; McMurray, J.J.; de Zeeuw, D.; Haffner, S.M.; Solomon, S.D.; Chaturvedi, N.; Persson, F.; Desai, A.S.; Nicolaides, M.; Richard, A.; et al. ALTITUDE Investigators Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 2012, 367, 2204-2213, doi:10.1056/NEJMoa1208799.
68. Harel, Z.; Gilbert, C.; Wald, R.; Bell, C.; Perl, J.; Juurlink, D.; Beyene, J.; Shah, P.S. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: Systematic review and meta-analysis. Br. Med. J. 2012, 344, e42, doi:10.1136/bmj.e42.
69. Bakris, G.L.; Oparil, S.; Purkayastha, D.; Yadao, A.M.; Alessi, T.; Sowers, J.R. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs. valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J. Clin. Hypertens. (Greenwich) 2013, 15, 92-100, doi:10.1111/jch.12032.
70. Waanders, F.; Visser, F.W.; Gans, R.O. Current concepts in the management of diabetic nephropathy. Neth. J. Med. 2013, 71, 448-558.
71. Bomback, A.S.; Kshirsagar, A.V.; Amamoo, M.A.; Klemmer, P.J. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review. Am. J. Kidney Dis. 2008, 51, 199-211, doi:10.1053/j.ajkd.2007.10.040.
72. Sato, A.; Hayashi, K.; Naruse, M.; Saruta, T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41, 64-68.
73. Rachmani, R.; Slavachevsky, I.; Amit, M.; Levi, Z.; Kedar, Y.; Berla, M.; Ravid, M. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study. Diabet. Med. 2004, 21, 471-475.
74. Mehdi, U.F.; Adams-Huet, B.; Raskin, P.; Vega, G.L.; Toto, R.D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 2009, 20, 2641-2650, doi:10.1681/ASN.2009070737.
75. E.; Millet, V.G.; Rojas-Rivera, J.; Huerta, A.; Gutiérrez, E.; Gutiérrez-Solís, E.; Egido, J.; Praga, M. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. Nephrol. Dial. Transplant. 2013, 28, 405-412, doi:10.1093/ndt/gfs429.
76. Epstein, M.; Williams, G.H.; Weinberger, M.; Lewin, A.; Krause, S.; Mukherjee, R.; Patni, R.; Beckerman, B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol. 2006, 1, 940-951.
77. Mavrakanas, T.A.; Gariani, K.; Martin, P.Y. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy: A systematic review. Eur. J. Intern. Med. 2014, 25, 173-176, doi:10.1016/j.ejim.2013.11.007.
78. Bakris, G.L.; Siomos, M.; Richardson, D.; Janssen, I.; Bolton, W.K.; Hebert, L.; Agarwal, R.; Catanzaro, D.; VAL-K Study Group. ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure. Kidney Int. 2000, 58, 2084-2092.
79. Persson, F.; Rossing, P. Sequential RAAS blockade: Is it worth the risk? Adv. Chronic Kidney Dis. 2014, 21, 159-165, doi:10.1053/j.ackd.2014.01.003.
80. Bakris, G.L.; Barnhill, B.W.; Sadler, R. Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney Int. 1992, 41, 912-919.
81. Böhlen, L.; de Courten, M.; Weidmann, P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am. J. Hypertens. 1994, 7, S84-S92.
82. Bakris, G.L.; Copley, J.B.; Vicknair, N.; Sadler, R.; Leurgans, S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996, 50, 1641-1650.
83. Bakris, G.L.; Weir, M.R.; DeQuattro, V.; McMahon, F.G. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998, 54, 1283-1289.
84. Vogt, L.; Waanders, F.; Boomsma, F.; de Zeeuw, D.; Navis, G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J. Am. Soc. Nephrol. 2008, 19, 999-1007, doi:10.1681/ASN.2007060693.
85. Houlihan, C.A.; Allen, T.J.; Baxter, A.L.; Panangiotopoulos, S.; Casley, D.J.; Cooper, M.E.; Jerums, G. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care 2002, 25, 663-671.
86. Slagman, M.C.; Waanders, F.; Hemmelder, M.H.; Woittiez, A.J.; Janssen, W.M.; Lambers Heerspink, H.J.; Navis, G.; Laverman, G.D.; Holland Nephrology Study Group. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: Randomised controlled trial. BMJ 2011, 343, doi:10.1136/bmj.d4366.
87. Lambers Heerspink, H.J.; Holtkamp, F.A.; Parving, H.H.; Navis, G.J.; Lewis, J.B.; Ritz, E.; de Graeff, P.A.; de Zeeuw, D. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int. 2012, 82, 330-337, doi:10.1038/ki.2012.74.
88. DiNicolantonio, J.J.; Pasquale, P.D.; Taylor, R.S.; Hackam, D.G. Low sodium versus normal sodium diets in systolic heart failure: Systematic review and meta-analysis. Heart 2013, doi:10.1136/heartjnl-2012-302337.
89. Esnault, V.L.; Ekhlas, A.; Delcroix, C.; Moutel, M.G.; Nguyen, J.M. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J. Am. Soc. Nephrol. 2005, 16, 474-481.
90. Collins, A.J.; Foley, R.N.; Chavers, B.; Gilbertson, D.; Herzog, C.; Ishani, A.; Johansen, K.; Kasiske, B.L.; Kutner, N.; Liu, J.; et al. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States; National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2013; doi:10.1053/j.ajkd.2013.11.001.
91. Hsu, T.W.; Liu, J.S.; Hung, S.C.; Kuo, K.L.; Chang, Y.K.; Chen, Y.C.; Hsu, C.C.; Tarng, D.C. Renoprotective effect of reninangiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern. Med. 2014, 174, 347-354, doi:10.1001/jamainternmed.2013.12700.
92. Yee, J. Diabetic Kidney Disease: An ACEI (or an ARB) in the Hole. Adv. Chronic Kidney Dis. 2014, 21, 251-255, doi:10.1053/j.ackd.2014.03.001.
93. Apperloo, A.J.; de Zeeuw, D.; de Jong, P.E. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int. 1997, 51, 793-797.
94. Holtkamp, F.A.; de Zeeuw, D.; Thomas, M.C.; Cooper, M.E.; de Graeff, P.A.; Hillege, H.J.; Parving, H.H.; Brenner, B.M.; Shahinfar, S.; Lambers Heerspink, H.J. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011, 80, 282-287, doi:10.1038/ki.2011.79.
95. Hansen, H.P.; Rossing, P.; Tarnow, L.; Nielsen, F.S.; Jensen, B.R.; Parving, H.H. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int. 1995, 47, 1726-1731, doi:10.1038/ki.1995.238
96. Onuigbo, M.A.; Onuigbo, N.T. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: A prospective 50-month Mayo-Health-System clinic analysis. QJM 2008, 101, 519-527, doi:10.1093/qjmed/hcn039.
97. Onuigbo, M.A. Radiographic contrast-induced nephropathy and patient mortality. Mayo Clin. Proc. 2008, 83, 1412-1413.
98. Onuigbo, M.A. Syndrome of rapid-onset end-stage renal disease: A new unrecognized pattern of CKD progression to ESRD. Ren. Fail. 2010, 32, 954-958, doi:10.3109/0886022X. 2010.502608.
99. Onuigbo, M.A. Evidence of the syndrome of rapid onset end-stage renal disease (SORO-ESRD) in the acute kidney injury (AKI) literature-Preventable causes of AKI and SORO-ESRD-A call for re-engineering of nephrology practice paradigms. Ren. Fail. 2013, 35, 796-800, doi:10.3109/0886022X.2013.800459.
100. Bjorck, S.; Mulec, H.; Johnsen, S.A.; Norden, G.; Aurell, M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992, 304, 339-343.
101. Anonymous. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998, 317, 713-720.
102. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein, H.C.; Miller, M.E.; Byington, R.P.; Goff, D.C., Jr.; Bigger, J.T.; Buse, J.B.; Cushman, W.C.; Genuth, S.; Ismail-Beigi, F.; Grimm, R.H., Jr., et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008, 358, 2545-2559, doi:10.1056/NEJMoa0802743.
103. The ACCORD Study Group; Cushman, W.C.; Evans, G.W.; Byington, R.P.; Goff, D.C., Jr.; Grimm, R.H., Jr.; Cutler, J.A.; Simons-Morton, D.G.; Basile, J.N.; Corson, M.A.; Probstfield, J.L.; et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 2010, 362, 1575-1585, doi:10.1056/NEJMoa1001286.
104. James, P.A.; Oparil, S.; Carter, B.L.; Cushman, W.C.; Dennison-Himmelfarb, C.; Handler, J.; Lackland, D.T.; LeFevre, M.L.; MacKenzie, T.D.; Ogedegbe, O.; et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA 2014, 311, 507-520, doi:10.1001/jama.2013.284427.
105. Khosla, N.; Kalaitzidis, R.; Bakris, G.L. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am. J. Nephrol. 2009, 30, 418-424, doi:10.1159/000237742.
106. Van Buren, P.N.; Adams-Huet, B. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clin J. Am. Soc. Nephrol. 2014, 9, 295-301, doi:10.2215/CJN.07460713.
107. Eijkelkamp, W.B.; Zhang, Z.; Remuzzi, G.; Parving, H.H.; Cooper, M.E.; Keane, W.F.; Shahinfar, S.; Gleim, G.W.; Weir, M.R.; Brenner, B.M.; et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J. Am. Soc. Nephrol. 2007, 18, 1540-1546.
108. Hou, F.F.; Xie, D.; Zhang, X.; Chen, P.Y.; Zhang, W.R.; Liang, M.; Guo, Z.J.; Jiang, J.P. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency. J. Am. Soc. Nephrol. 2007, 18, 1889-1898.
109. Rossing, K.; Schjoedt, K.J.; Jensen, B.R.; Boomsma, F.; Parving, H.H. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005, 68, 1190-1198.
110. Burgess, E.; Muirhead, N.; Rene de Cotret, P.; Chiu, A.; Pichette, V.; Tobe, S.; SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J. Am. Soc. Nephrol. 2009, 20, 893-900
111. Wheeler, D.C.; Becker, G.J. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int. 2013, 83, 377-383, doi:10.1038/ki.2012.425.
112. Taler, S.J.; Agarwal, R.; Bakris, G.L.; Flynn, J.T.; Nilsson, P.M.; Rahman, M.; Sanders, P.W.; Textor, S.C.; Weir, M.R.; Townsend, R.R. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am. J. Kidney Dis. 2013, 62, 201-213, doi:10.1053/j.ajkd.2013.03.018.
113. Yamout, H.; Lazich, I.; Bakris, G.L. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease. Adv. Chronic Kidney Dis. 2014, 21, 281-286, doi:10.1053/j.ackd.2014.03.005.
114. Wong, J.; Molyneaux, L.; Constantino, M.; Twigg, S.M.; Yue, U.K. Beyond ONTARGET: Angiotensin-converting enzyme inhibition and angiotensin II receptor blockade in combination, a lesser evil in some? Diabetes Obes. Metab. 2010, 12, 1072-1078, doi:0.1111/j.1463-1326.2010.01298.x.